Find a copy in the library
Finding libraries that hold this item...
|All Authors / Contributors:||
Shaker A Mousa; Paul J Davis, (Professor of pharmacy)
|ISBN:||9789400764668 9400764669 9400764677 9789400764675|
|Description:||x, 206 pages : illustrations|
|Contents:||Preface. 1. Angiogenesis assays: an appraisal of current techniques. 2. Survey of pro-angiogenesis strategies. 3. Angiogenesis modulation by arachidonic acid - derived lipids: positive and negative regulators of angiogenesis. 4. Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects. 5. Actions of steroids and peptide hormones on angiogenesis. 6. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation. 7. Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment. 8. Impact of nanotechnology on therapeutic angiogenesis. 9. Survey of anti-angiogenesis strategies. 10. Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis. 11. Integrin antagonists and angiogenesis. 12. Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology. 13. Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration. 14. Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit. 15. Biomarkers of response and resistance to anti-angiogenic treatment.16. Speculations on new directions in which angiogenesis may proceed. Index.|
|Responsibility:||Shaker A. Mousa, Paul J. Davis, editors.|